CHEN, YOUNG K.,KANOUNI, TOUFIKE,KALDOR, STEPHEN W.,STAFFORD, JEFFREY ALAN,VEAL, JAMES MARVIN,TAVARES-GRECO, PAULA ALESSANDRA,KREILEIN, MATTHEW MICHAEL
申请号：
CA3004300
公开号：
CA3004300A1
申请日:
2016.11.04
申请国别(地区):
CA
年份:
2017
代理人:
摘要：
Described herein are amorphous and crystalline forms of pharmaceuticallyacceptable salts of the lysine specific demethylase-1inhibitor 4-[2-(4-amino-piperidin-1-yl)-5-(3-fluoro-4-methoxy-phenyl)-1-methyl-6-oxo-1,6-dihydro-pyrimidin-4-yl]- 2-fluorobenzonitrile.Also described are pharmaceutical compositions suitable for administration toa mammal that include the lysinespecific demethylase-1 inhibitor, and methods of using the lysine specificdemethylase-1 inhibitor for treating diseases or conditionsthat are associated with lysine specific demethylase-1 activity.
